Stock Worth Mentioning Today: Delcath Systems, Inc. Can’t Be More Risky. Just Reaches All-Time Low

Stock Worth Mentioning Today: Delcath Systems, Inc. Can't Be More Risky. Just Reaches All Time Low

The stock of Delcath Systems, Inc. (NASDAQ:DCTH) reached all time low today, Oct, 17 and still has $2.07 target or 12.00% below today’s $2.35 share price. This indicates more downside for the $4.26 million company. This technical setup was reported by If the $2.07 PT is reached, the company will be worth $511,200 less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 53,309 shares traded hands or 31.26% up from the average. Delcath Systems, Inc. (NASDAQ:DCTH) has declined 58.39% since March 14, 2016 and is downtrending. It has underperformed by 64.00% the S&P500.

Analysts await Delcath Systems, Inc. (NASDAQ:DCTH) to report earnings on November, 8.

According to Zacks Investment Research, “Delcath Systems, Inc. has developed a system, the Delcath system, to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver.”

Insitutional Activity: The institutional sentiment decreased to 1.13 in Q2 2016. Its down 0.30, from 1.43 in 2016Q1. The ratio dived, as 7 funds sold all Delcath Systems, Inc. shares owned while 1 reduced positions. 2 funds bought stakes while 7 increased positions. They now own 1.85 million shares or 18.13% less from 2.26 million shares in 2016Q1.
Group One Trading L P accumulated 0% or 5,123 shares. The Germany-based Deutsche Commercial Bank Ag has invested 0% in Delcath Systems, Inc. (NASDAQ:DCTH). Ladenburg Thalmann Finance Inc owns 1,456 shares or 0% of their US portfolio. Vanguard Grp Inc owns 77,988 shares or 0% of their US portfolio. Kcg Inc accumulated 0% or 12,403 shares. Barclays Plc holds 15 shares or 0% of its portfolio. Renaissance Techs Lc accumulated 0% or 754,998 shares. Royal Natl Bank Of Canada has 2,563 shares for 0% of their US portfolio. Citadel Advsrs Limited Liability Corporation reported 157,333 shares or 0% of all its holdings. Wells Fargo Co Mn owns 157 shares or 0% of their US portfolio. Goldman Sachs Gp, a New York-based fund reported 15,211 shares. Creative Planning reported 307 shares or 0% of all its holdings. Geode Capital Ltd Llc reported 39,792 shares or 0% of all its holdings. Private Advisor Limited Liability Co last reported 0% of its portfolio in the stock. Blackrock Institutional Tru Na has 531,871 shares for 0% of their US portfolio.

More notable recent Delcath Systems, Inc. (NASDAQ:DCTH) news were published by: which released: “Delcath Systems Inc.” on December 22, 2009, also with their article: “Delcath Sponsors Ocular Melanoma Foundation Patient Retreat” published on September 19, 2016, published: “Delcath To Present At The 2016 Aegis Growth Conference” on September 12, 2016. More interesting news about Delcath Systems, Inc. (NASDAQ:DCTH) were released by: and their article: “European Data Supporting Survival Benefit With Delcath’s CHEMOSAT System …” published on July 06, 2016 as well as‘s news article titled: “Pomerantz Law Firm Has Filed a Class Action Against Delcath Systems, Inc. and …” with publication date: May 08, 2013.

DCTH Company Profile

Delcath Systems, Inc., incorporated on August 5, 1988, is a late-stage clinical development firm with early commercial activity in Europe focused on cancers of the liver. The Firm is a specialty pharmaceutical and medical device firm developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company’s system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company’s focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment